Study details
Enrolling now
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
ONL Therapeutics
NCT IDNCT06659445ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
324
Study length
about 3.1 years
Ages
55+
Locations
27 sites in AZ, CA, CO +14
What this study is about
This trial is testing a treatment called ONL1204 for people with geographic atrophy (GA) linked to age-related macular degeneration (AMD). The goal is to see if this treatment helps improve vision and is safe.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Avacincaptad Pegol intravitreal solution
- 2.Sham
- 3.Take ONL1204 Opthalmic solution
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IVintravitreal
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
avacincaptad pegol
Drug routes
injection, intravitreal
Endpoints
Primary: Primary Endpoint